David A. Nathanson

6.6k total citations · 1 hit paper
63 papers, 1.4k citations indexed

About

David A. Nathanson is a scholar working on Genetics, Molecular Biology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, David A. Nathanson has authored 63 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Genetics, 19 papers in Molecular Biology and 19 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in David A. Nathanson's work include Glioma Diagnosis and Treatment (23 papers), Cancer, Hypoxia, and Metabolism (12 papers) and Medical Imaging Techniques and Applications (9 papers). David A. Nathanson is often cited by papers focused on Glioma Diagnosis and Treatment (23 papers), Cancer, Hypoxia, and Metabolism (12 papers) and Medical Imaging Techniques and Applications (9 papers). David A. Nathanson collaborates with scholars based in United States, Japan and Denmark. David A. Nathanson's co-authors include Timothy F. Cloughesy, Johannes Czernin, Linda M. Liau, Steven J. Bensinger, Ken Herrmann, Lisa Ta, X. Wilson, Martin Allen-Auerbach, Robert M. Prins and Richard G. Everson and has published in prestigious journals such as Journal of the American Chemical Society, Angewandte Chemie International Edition and Nature Medicine.

In The Last Decade

David A. Nathanson

58 papers receiving 1.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

CDKN2A deletion remodels lipid metabolism to prime glioblastoma for ferroptosis

2023 102 citations Danielle Morrow, Nicholas Bayley et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
David A. Nathanson United States	23	581	356	346	328	231	63	1.4k
Matthew E. Hardee United States	17	419 0.7×	373 1.0×	327 0.9×	441 1.3×	190 0.8×	31	1.4k
Felix Zeppernick Germany	17	609 1.0×	384 1.1×	290 0.8×	691 2.1×	91 0.4×	40	1.6k
John A. Ronald Canada	19	669 1.2×	194 0.5×	159 0.5×	330 1.0×	345 1.5×	70	1.8k
Edward Pan United States	26	709 1.2×	347 1.0×	881 2.5×	388 1.2×	370 1.6×	79	1.9k
Antonella Zannetti Italy	27	1.1k 1.8×	426 1.2×	157 0.5×	669 2.0×	278 1.2×	66	2.0k
Rushdia Z. Yusuf United States	14	1.1k 1.9×	488 1.4×	345 1.0×	418 1.3×	91 0.4×	26	2.3k
Matthias Holdhoff United States	27	596 1.0×	267 0.8×	821 2.4×	604 1.8×	345 1.5×	111	2.1k
Ningjing Lin China	15	457 0.8×	201 0.6×	362 1.0×	609 1.9×	76 0.3×	66	1.4k
Pei Yang China	22	530 0.9×	520 1.5×	613 1.8×	281 0.9×	133 0.6×	46	1.3k
Patrick Healy United States	24	592 1.0×	392 1.1×	374 1.1×	970 3.0×	140 0.6×	98	2.0k

Countries citing papers authored by David A. Nathanson

Since Specialization

Citations

This map shows the geographic impact of David A. Nathanson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David A. Nathanson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David A. Nathanson more than expected).

Fields of papers citing papers by David A. Nathanson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David A. Nathanson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David A. Nathanson. The network helps show where David A. Nathanson may publish in the future.

Co-authorship network of co-authors of David A. Nathanson

This figure shows the co-authorship network connecting the top 25 collaborators of David A. Nathanson. A scholar is included among the top collaborators of David A. Nathanson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David A. Nathanson. David A. Nathanson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Sanvito, Francesco, Catalina Raymond, Richard G. Everson, et al.. (2025). Impact of corticosteroid administration on contrast-enhancing volume and diffusion MRI in treatment naïve glioblastoma. Neuro-Oncology. 27(11). 3016–3026.

Zhu, Yichen, Zhe Li, Aiqi Zhao, et al.. (2025). Allogeneic stem cell-engineered EGFRvIII-specific CAR-NKT cells for treating glioblastoma with enhanced efficacy and safety. Molecular Therapy. 33(12). 6041–6062. 3 indexed citations

Fernández, Elízabeth, X. Wilson, Nicholas Bayley, et al.. (2024). Integrated molecular and functional characterization of the intrinsic apoptotic machinery identifies therapeutic vulnerabilities in glioma. Nature Communications. 15(1). 10089–10089. 4 indexed citations

Hou, Andrew J., Benjamin R. Uy, Begonya Comin-Anduix, et al.. (2024). IL-13Rα2/TGF-β bispecific CAR-T cells counter TGF-β-mediated immune suppression and potentiate anti-tumor responses in glioblastoma. Neuro-Oncology. 26(10). 1850–1866. 32 indexed citations

Kornblum, Harley I., David A. Nathanson, Matteo Pellegrini, et al.. (2024). D-2-HG Inhibits IDH1mut Glioma Growth via FTO Inhibition and Resultant m6A Hypermethylation. Cancer Research Communications. 4(3). 876–894. 8 indexed citations

Tsang, Jonathan, et al.. (2023). ¹⁸F-Labeled brain-penetrant EGFR tyrosine kinase inhibitors for PET imaging of glioblastoma. Chemical Science. 14(47). 13825–13831. 2 indexed citations

Li, Matthew, et al.. (2023). STEM-22. SINGLE-CELL LINEAGE TRACING IN PRIMARY GLIOBLASTOMA REVEALS DISTINCT PROGENITOR SUBTYPES DRIVING INTRATUMORAL HETEROGENEITY. Neuro-Oncology. 25(Supplement_5). v37–v37.

Ellingson, Benjamin M., Akifumi Hagiwara, Nicholas S. Cho, et al.. (2023). Depth of Radiographic Response and Time to Tumor Regrowth Predicts Overall Survival Following Anti-VEGF Therapy in Recurrent Glioblastoma. Clinical Cancer Research. 29(20). 4186–4195. 5 indexed citations

Desousa, Brandon R., Kristen K.O. Kim, Anthony E. Jones, et al.. (2023). Calculation of ATP production rates using the Seahorse XF Analyzer. EMBO Reports. 24(10). e56380–e56380. 41 indexed citations

10.

Morrow, Danielle, Nicholas Bayley, Elízabeth Fernández, et al.. (2023). TMET-12. CDKN2A DELETION REMODELS LIPID METABOLISM TO PRIME GLIOBLASTOMA FOR FERROPTOSIS. Neuro-Oncology. 25(Supplement_5). v275–v275. 1 indexed citations

11.

Alvarado, Alvaro G., Sree Deepthi Muthukrishnan, Riki Kawaguchi, et al.. (2022). Pathway-based Approach Reveals Differential Sensitivity to E2F1 Inhibition in Glioblastoma. Cancer Research Communications. 2(9). 1049–1060. 4 indexed citations

12.

Bhat, Kruttika, Fei Cheng, Ling He, et al.. (2021). Dopamine Receptor Antagonists, Radiation, and Cholesterol Biosynthesis in Mouse Models of Glioblastoma. JNCI Journal of the National Cancer Institute. 113(8). 1094–1104. 24 indexed citations

13.

Lee, Alex, Lu Sun, Aaron Mochizuki, et al.. (2021). Neoadjuvant PD-1 blockade induces T cell and cDC1 activation but fails to overcome the immunosuppressive tumor associated macrophages in recurrent glioblastoma. Nature Communications. 12(1). 6938–6938. 135 indexed citations

14.

Ellingson, Benjamin M., Jingwen Yao, Catalina Raymond, et al.. (2020). Multiparametric MR-PET Imaging Predicts Pharmacokinetics and Clinical Response to GDC-0084 in Patients with Recurrent High-Grade Glioma. Clinical Cancer Research. 26(13). 3135–3144. 10 indexed citations

15.

Tsang, Jonathan, Gyudong Kim, Kingsley Chow, et al.. (2020). Development of a Potent Brain-Penetrant EGFR Tyrosine Kinase Inhibitor against Malignant Brain Tumors. ACS Medicinal Chemistry Letters. 11(10). 1799–1809. 23 indexed citations

16.

Xiao, Weikun, Rongyu Zhang, Alireza Sohrabi, et al.. (2017). Brain-Mimetic 3D Culture Platforms Allow Investigation of Cooperative Effects of Extracellular Matrix Features on Therapeutic Resistance in Glioblastoma. Cancer Research. 78(5). 1358–1370. 69 indexed citations

17.

Laks, Dan R., Lisa Ta, Thomas J. Crisman, et al.. (2016). Inhibition of Nucleotide Synthesis Targets Brain Tumor Stem Cells in a Subset of Glioblastoma. Molecular Cancer Therapeutics. 15(6). 1271–1278. 12 indexed citations

18.

Wang, Jun, Kiwook Hwang, Daniel Braas, et al.. (2013). Fast Metabolic Response to Drug Intervention Through Analysis on a Miniaturized, Highly Integrated Molecular Imaging System. Journal of Nuclear Medicine. 54(10). 1820–1824. 9 indexed citations

19.

Braas, Daniel, Ethan Ahler, David A. Nathanson, et al.. (2012). Metabolomics Strategy Reveals Subpopulation of Liposarcomas Sensitive to Gemcitabine Treatment. Cancer Discovery. 2(12). 1109–1117. 27 indexed citations

20.

Yoshimoto, Koji, Julie Dang, Shaojun Zhu, et al.. (2008). Development of a Real-time RT-PCR Assay for Detecting EGFRvIII in Glioblastoma Samples. Clinical Cancer Research. 14(2). 488–493. 81 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact